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Effect of Trazodone on Upper Airway Resistance in Chronic Spinal Cord Injury 
Geoffrey Ginter, Sean Carroll, Abdulghani Sankari, M. Safwan Badr 
Background: 
Spinal cord injury (SCI) is a known risk factor for sleep-disordered breathing. While device-based 
therapies such as CPAP are beneficial in these individuals, adherence to these treatments is often low; 
consequently, pharmacotherapies for sleep-disordered breathing in patients with SCI are in high 
demand. Trazodone is an atypical antidepressant with a complex mechanism of action, including alpha 
adrenergic agonist activity and inhibition of serotonin reuptake. Serotonin (5-HT) is a known modulator 
of respiratory circuitry, which has been shown to influence the ventilatory drive. Trazodone is commonly 
prescribed as a sleep aid, but its impact on breathing during sleep is still unclear.  
Methods: 
 We randomized 9 participants with chronic spinal cord injury and sleep-disordered breathing to receive 
either placebo or trazodone 100 mg for seven days. On day 7, participants underwent polysomnography 
with a supraglottic pressure catheter to determine upper airway pressure. Participants then underwent 
a 1-week washout period before crossing over to the other medication and repeating the same protocol. 
Parameters of interest included apnea-hypopnea index (AHI), obstructive apnea index (OAI), central 
apnea index (CAI), oxyhemoglobin desaturation index (ODI), and upper airway resistance (RUA). 
Results: 
7 participants completed polysomnography on both medications, 5 of which had adequate data to 
calculate RUA. Trazodone did not result in significant improvement in AHI (47.86±24.27 on placebo vs 
28.73±28.79 on trazodone, p=0.10), OAI (9.29±9.48 vs 2.86±3.39, p=0.13), CAI (1.14±1.46 vs 1.71±3.30, 
p=0.52), ODI (25.00±28.39 vs 19.44±33.61, p=0.34), or RUA (2.47±0.92 vs 8.98±11.02, p=0.23). 
Conclusion: 
Based on our preliminary data in a small number of subjects, trazodone is not effective in treating sleep-
disordered breathing in individuals with spinal cord injury. Due to the limited sample size, our data may 
not accurately represent the clinical utility of trazodone, and further study in a larger number of patients 
is warranted. 
 
